Cancer immunotherapy: Wound-bound checkpoint blockade

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

(2017) Chao Wang et al.   Nature Biomedical Engineering

P-012CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer

(2016) J. Zhang et al.   ANNALS OF ONCOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelets at the interface of thrombosis, inflammation, and cancer

(2015) A. T. Franco et al.   BLOOD

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Nanoparticle biointerfacing by platelet membrane cloaking

(2015) Che-Ming J. Hu et al.   NATURE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY